Gary R. Lichtenstein

425 total citations
19 papers, 301 citations indexed

About

Gary R. Lichtenstein is a scholar working on Epidemiology, Genetics and Surgery. According to data from OpenAlex, Gary R. Lichtenstein has authored 19 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 10 papers in Genetics and 7 papers in Surgery. Recurrent topics in Gary R. Lichtenstein's work include Inflammatory Bowel Disease (10 papers), Microscopic Colitis (8 papers) and Helicobacter pylori-related gastroenterology studies (2 papers). Gary R. Lichtenstein is often cited by papers focused on Inflammatory Bowel Disease (10 papers), Microscopic Colitis (8 papers) and Helicobacter pylori-related gastroenterology studies (2 papers). Gary R. Lichtenstein collaborates with scholars based in United States, United Kingdom and Italy. Gary R. Lichtenstein's co-authors include Chinyu Su, Linda B. Hurd, Emma E. Furth, Gary D. Wu, Mitchell A. Lazar, Robert B. Stein, Ejigayehu Demissie, Franz Fogt, Thomas Judge and James D. Lewis and has published in prestigious journals such as Gastroenterology, The American Journal of Gastroenterology and Journal of the American Academy of Dermatology.

In The Last Decade

Gary R. Lichtenstein

17 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary R. Lichtenstein United States 8 107 103 100 77 55 19 301
Rebecca Roberts New Zealand 5 63 0.6× 151 1.5× 58 0.6× 57 0.7× 92 1.7× 7 313
Kumi Ishida Japan 11 134 1.3× 90 0.9× 50 0.5× 74 1.0× 68 1.2× 31 343
Brian Ko United States 8 180 1.7× 109 1.1× 188 1.9× 139 1.8× 90 1.6× 13 483
Armine Avanesyan United States 5 57 0.5× 140 1.4× 65 0.7× 78 1.0× 258 4.7× 7 436
Mara Oliveri Italy 9 46 0.4× 42 0.4× 124 1.2× 43 0.6× 111 2.0× 9 379
Masaaki Natsui Japan 9 164 1.5× 57 0.6× 68 0.7× 30 0.4× 73 1.3× 13 320
Jiannan Li China 11 51 0.5× 80 0.8× 91 0.9× 45 0.6× 76 1.4× 28 350
Kiyoto Mori Japan 8 63 0.6× 164 1.6× 65 0.7× 124 1.6× 106 1.9× 12 314
Valle Cadahía Spain 12 79 0.7× 108 1.0× 43 0.4× 298 3.9× 57 1.0× 20 468
De Kai QIU China 11 126 1.2× 77 0.7× 88 0.9× 371 4.8× 118 2.1× 14 548

Countries citing papers authored by Gary R. Lichtenstein

Since Specialization
Citations

This map shows the geographic impact of Gary R. Lichtenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary R. Lichtenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary R. Lichtenstein more than expected).

Fields of papers citing papers by Gary R. Lichtenstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary R. Lichtenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary R. Lichtenstein. The network helps show where Gary R. Lichtenstein may publish in the future.

Co-authorship network of co-authors of Gary R. Lichtenstein

This figure shows the co-authorship network connecting the top 25 collaborators of Gary R. Lichtenstein. A scholar is included among the top collaborators of Gary R. Lichtenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary R. Lichtenstein. Gary R. Lichtenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Panaccione, Remo, Séverine Vermeire, Silvio Danese, et al.. (2025). Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study. ˜The œLancet. Gastroenterology & hepatology. 10(6). 507–519. 2 indexed citations
2.
Lichtenstein, Gary R., Jessica R. Allegretti, David T. Rubin, et al.. (2025). Su1856: EFFICACY AND SAFETY OF GUSELKUMAB FOR ULCERATIVE COLITIS THROUGH WEEK 92 OF THE QUASAR LONG-TERM EXTENSION STUDY. Gastroenterology. 169(1). S–861.
3.
Rubin, David T., Jessica R. Allegretti, Julián Panés, et al.. (2024). 759 THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY. Gastroenterology. 166(5). S–180. 14 indexed citations
4.
Allegretti, Jessica R., Laurent Peyrin‐Biroulet, Brian G. Feagan, et al.. (2023). 913b THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY. Gastroenterology. 164(6). S–1572. 7 indexed citations
5.
Panaccione, Remo, Gary R. Lichtenstein, Hiroshi Nakase, et al.. (2023). Tu1732 SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE). Gastroenterology. 164(6). S–1100. 1 indexed citations
6.
Lichtenstein, Gary R., Brian G. Feagan, Jay Tuttle, et al.. (2020). Tu1887 IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A PHASE 2 STUDY ANALYSIS USING THE SF-36 V2 STANDARD. Gastroenterology. 158(6). S–1204. 1 indexed citations
7.
Lichtenstein, Gary R., Edward V. Loftus, Stuart Bloom, et al.. (2018). Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment. The American Journal of Gastroenterology. 113(Supplement). S329–S329. 7 indexed citations
8.
Lichtenstein, Gary R., Matthew A. Ciorba, Gerhard Rogler, et al.. (2018). Sa1763 - Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Malignancy Rates from the Octave Clinical Program. Gastroenterology. 154(6). S–385. 3 indexed citations
9.
Lichtenstein, Gary R., et al.. (2007). MMX™ Mesalamine Is Effective for the Maintenance of Ulcerative Colitis Remission in Both Left-Sided and Extensive Disease. The American Journal of Gastroenterology. 102. S462–S462. 4 indexed citations
10.
Lichtenstein, Gary R.. (2007). Introduction. Yearbook of Gastroenterology. 2007. 107–107. 1 indexed citations
11.
Lichtenstein, Gary R.. (2007). Monitoring 6-Mercaptopurine/Azathioprine Metabolite Levels. The American Journal of Gastroenterology. 102. 14–17. 1 indexed citations
12.
Lewis, James D., Gary R. Lichtenstein, Robert B. Stein, et al.. (2001). An open-label trial of the PPARgamma ligand rosiglitazone for active ulcerative colitis. The American Journal of Gastroenterology. 96(12). 3323–3328. 147 indexed citations
13.
Lichtenstein, Gary R.. (2001). Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease. Inflammatory Bowel Diseases. 7(S1). S23–S29. 22 indexed citations
14.
Lichtenstein, Gary R., et al.. (2000). A new endoscopic technique for the removal of gastric phytobezoars. Gastrointestinal Endoscopy. 52(3). 404–408. 51 indexed citations
15.
Lipson, David A., Jesse A. Berlin, Harold I. Palevsky, et al.. (1998). Giant Gastric Ulcers and Risk Factors for Gastroduodenal Mucosal Disease in Orthotopic Lung Transplant Patients. Digestive Diseases and Sciences. 43(6). 1177–1185. 11 indexed citations
16.
Lichtenstein, Gary R. & Marta A. Dabezies. (1998). Biliary tract dysmotility. Current Treatment Options in Gastroenterology. 1(1). 27–34. 2 indexed citations
17.
Lichtenstein, Gary R., et al.. (1994). Localization and inhibitory actions of galanin at the feline lower esophageal sphincter. Regulatory Peptides. 50(3). 213–222. 3 indexed citations
18.
Lichtenstein, Gary R.. (1994). Medical therapies for inflammatory bowel disease. Current Opinion in Gastroenterology. 10(4). 390–403. 4 indexed citations
19.
Olsen, Elise A., Gary R. Lichtenstein, & William E. Wilkinson. (1988). Changes in serum lipids in patients with condylomata acuminata treated with interferon alfa-nl (Wellferon). Journal of the American Academy of Dermatology. 19(2). 286–289. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca Roberts Breakdown of academic impact, for papers by Kumi Ishida Breakdown of academic impact, for papers by Brian Ko Breakdown of academic impact, for papers by Armine Avanesyan Breakdown of academic impact, for papers by Mara Oliveri Breakdown of academic impact, for papers by Masaaki Natsui Breakdown of academic impact, for papers by Jiannan Li Breakdown of academic impact, for papers by Kiyoto Mori Breakdown of academic impact, for papers by Valle Cadahía Breakdown of academic impact, for papers by De Kai QIU
Rankless by CCL
2026